Connect with us

Technology

Elsevier launches ScienceDirect AI to transform research with rapid mission-critical insights from trusted content

Published

on

New generative AI tool on ScienceDirect, the world’s largest platform for peer-reviewed research used by millions of researchers each day, saves half of literature research time, supports better outcomes

LONDON, March 12, 2025 /PRNewswire/ — Elsevier, a global leader in advanced information and decision support, today launches ScienceDirect AI, a cutting-edge generative AI tool for researchers. It is designed to transform the way researchers work by enabling them to instantly extract, summarize and compare trusted insights from millions of full-text articles and book chapters on ScienceDirect, the world’s largest platform for trusted, peer-reviewed research.

 

Researchers grapple with an ever-growing and overwhelming volume of information and need to quickly get accurate insights they can rely on. Studies show that they spend 25%-35% of their time sifting through literature. ScienceDirect AI helps address this challenge by drawing on the broadest and deepest content set of millions of peer-reviewed full-text research articles and book chapters to generate instant accurate summaries and highlight key findings, while providing references to support the reproducibility and integrity of research.

Broadest and deepest verified content set with power of generative AI: ScienceDirect AI surfaces insights from the world’s largest corpus of peer-reviewed full-text articles and book chapters.

Traceable claims, rooted in the scientific record, shown in context: Traceability and reproducibility of information are vital for research integrity. To ensure reliable insights that can be replicated, ScienceDirect AI provides clear links to sources of information and claims, including exact passages within research articles, offering the option to explore further. 

Responsible AI: ScienceDirect AI is purposefully built to ensure accuracy and reduce the risk of hallucinations and biases. Users can transparently see how the tool reaches answers. 

Developed with and for researchers: Over 30,000 researchers and librarians from 70 universities and R&D intensive corporations globally helped test and develop ScienceDirect AI. Building on the feedback received, the tool can save 50% of time spent on literature research and help to enhance their research.

ScienceDirect AI includes the following features:

Ask ScienceDirect AI – search and summaries of full-text articles and book chapters

Users can search and get answers from within the full-text of 14 million articles and book chapters, using their own words to describe what they need and why. ScienceDirect AI will search across the millions of documents in its index to provide a Summary Response with references, Source Snippets for each reference, and short Related Insights summaries while linking back to the original document. 

Reading Assistant – chat with a document in ScienceDirect

This conversational feature answers questions about the content of a specific full-text article or book chapter and allows researchers to ask further questions of the document. Users can click on references within the summaries to jump to locations in the article where the answer comes from, it also suggests research questions. 

Compare Experiments – experiment summary table

Comparing and synthesizing literature can be very time-consuming. ScienceDirect AI’s unique Compare Experiments tool takes a set of articles and creates a table breaking down each experiment within them, drawing out the key aspects of each including goals, methods and results. 

Judy Verses, Elsevier President of Academic and Government Markets, said: “Feedback from users worldwide suggests ScienceDirect AI could be a game changer for researchers who are grappling with information overload and want to get accurate insights they can rely on, fast. ScienceDirect is the platform of choice globally for millions of researchers, so this new generative AI tool will seamlessly integrate into their current ways of working, enabling them to dedicate more time to research and achieve results. We are committed to working with researchers to continually develop innovative solutions to help them advance science and human progress.” 

Matías Montero, PhD Student in the Department of Education, University of Oxford, who has taken part in ScienceDirect AI testing, said: “I’ve been thinking about how much time ScienceDirect AI has saved me lately. I estimate that with all the core features I use – search, reading assistant, and uploading and querying my own PDFs – I’m saving about an hour each day on my research workflow. It’s very valuable! It lets me dive deeper into reading relevant, important papers and dedicate more hours to writing, instead of getting lost in search or manually pulling out key takeaways.” 

Professor Paulo Botelho Pires, from the Accounting and Business School at Porto Institute, who has taken part in ScienceDirect AI testing, said: “ScienceDirect’s AI tool has transformed the way I work. Amidst an ecosystem with AI tools that hallucinate or provide false information, this tool stands out for its precision. The quality of information I receive spares me hours of search. Its effectiveness has allowed me to expand the scope of my research projects, investigate more diverse lines of research, and produce superior work.” 

Elsevier is partnering with the research community to develop solutions that help researchers more easily discover, analyze and synthesize research using trusted content powered by responsible AI. Scopus AI, launched in January 2024, draws on Scopus’ curated collection of research data and abstracts from over 7,000 publishers globally. Like a telescope, Scopus AI provides a broad view of the full research landscape and helps to make interdisciplinary connections to support strategy and planning. ScienceDirect AI is complementary, providing a microscopic deep-dive into millions of full-text articles and book chapters, for detailed analysis. By integrating its high-quality trusted content and data with responsible AI across its platforms, Elsevier aims to help advance science, to advance human progress. 

ScienceDirect AI was developed in line with Elsevier’s Responsible AI Principles and Privacy Principles to ensure the highest standards of data privacy and security. ScienceDirect AI’s use of third-party LLMs is private, no information is stored or used to train public models, and all data is stored in a protected and private environment exclusive to Elsevier. ScienceDirect is ISO27001 compliant. For more than a decade, Elsevier has been using AI and machine learning technologies in its products combined with its unparalleled peer-reviewed content, extensive data sets and sophisticated analytics to help researchers, clinicians, students and educators achieve their goals.  

ScienceDirect AI is available to purchase now for customers. For further information and contact details, please visit: http://elsevier.io/sciencedirect-ai 

Notes to editors 

Data taken from studies in the UK and Australia

About Elsevier

A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.

Logo: https://mma.prnewswire.com/media/2628519/5198935/Elsevier_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/elsevier-launches-sciencedirect-ai-to-transform-research-with-rapid-mission-critical-insights-from-trusted-content-302398829.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

VERNAL CAPITAL ACQUISITION CORP. ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING

Published

on

By

NEW YORK, May 5, 2026 /PRNewswire/ — Vernal Capital Acquisition Corp. (NYSE: VECA) (“Vernal”) announced the pricing of its initial public offering (the “IPO”) of 10,000,000 units at $10.00 per unit. The units are expected to trade on the New York Stock Exchange (“NYSE”) under “VECAU” beginning May 6, 2026. Each unit consists of one ordinary share and one right to receive one-fourth of one ordinary share upon consummation of an initial business combination. Upon separate trading, the ordinary shares and rights are expected to be listed on NYSE under “VECA” and “VECAR,” respectively.

D. Boral Capital LLC is acting as sole book-running manager of the offering. The underwriters have a 45-day option to purchase up to 1,500,000 additional units to cover any over-allotments. The offering is expected to close on May 7, 2026, subject to customary closing conditions.

A registration statement for these securities was declared effective by the SEC on May 5, 2026. The offering is made only by means of a prospectus. Copies of the prospectus may be obtained, from D. Boral Capital LLC, 590 Madison Ave., 39th Floor, New York, New York 10022, by telephone at (212) 970-5150 or by email at dbccapitalmarkets@dboralcapital.com.

This press release shall not constitute an offer to sell or to buy, nor shall there be any sale where such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws.

About Vernal

Vernal is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Vernal’s target search will not be limited to a particular industry or geographic region.

Forward-Looking Statements

This press release contains “forward-looking statements,” including statements regarding Vernal’s IPO. These statements are subject to risks and uncertainties that could cause actual results to differ materially. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, beyond Vernal’s control, including those in the Risk Factors section of Vernal’s registration statement filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Vernal disclaims any obligation to release publicly updates or revisions to any forward-looking statements to reflect any change in Vernal’s expectations, except as required by law.

Contact

Binghan Yi, CFO
binghan@vernal.com
www.vernalspac.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vernal-capital-acquisition-corp-announces-pricing-of-100-million-initial-public-offering-302763378.html

SOURCE Vernal Capital Acquisition Corp.

Continue Reading

Technology

RIVANNA nominated for MedTech Scale-Up of the Year at MedTech World Awards 2026 | North America

Published

on

By

Nomination places the Charlottesville-based company among growth-stage medtech leaders recognized for commercial momentum in AI-powered clinical decision support; public voting is open through May 8

CHARLOTTESVILLE, Va., May 5, 2026 /PRNewswire/ — RIVANNA®, developer of AI-powered clinical decision-support solutions, today announced that it has been nominated for MedTech Scale-Up of the Year at the MedTech World Awards 2026 | North America. Public voting is open through Friday, May 8, 2026, with category winners to be announced at the inaugural North American Awards Gala on May 11, 2026, at the Hilton West Palm Beach in Florida.

The MedTech Scale-Up of the Year category honors a growth-stage company successfully scaling revenues, partnerships, and adoption across the global medical technology ecosystem. Nominees across the program’s 22 categories were selected through a structured process led by the MedTech World Steering Committee, with category winners determined by a combination of expert evaluation and public voting from the global MedTech community.

“We have built RIVANNA on validation earned from the most rigorous technical buyers in healthcare: competitive federal awards translated into FDA-cleared products, each paired with a commercial program that meets clinicians where they work,” said Will Mauldin, PhD, Co-founder and CEO of RIVANNA. “Being nominated for MedTech Scale-Up of the Year is a meaningful affirmation of that approach and the team executing it.”

Public voting closes Friday, May 8, 2026. Members of the MedTech community are invited to support RIVANNA’s nomination at the official voting page: vote here.

The award nomination follows a year of measurable scaling for RIVANNA:

In October 2025, RIVANNA reported on being named a finalist in MedTech Innovator’s 2025 Early-Stage Grand Prize competition, selected from nearly 1,500 global applicants to represent the top 4% of medtech innovations worldwide.In December 2025, RIVANNA reported on the U.S. Food and Drug Administration’s 510(k) clearance of its Accuro® 3S Needle Guide Kit consumables, building on existing Accuro 3S device clearance.In April 2026, RIVANNA reported on peer-reviewed findings, published in 2025 in the Journal of Emergency Medicine (DOI: 10.1016/j.jemermed.2025.11.011), showing that the Accuro® XV musculoskeletal imaging system enables non-physician operators to acquire diagnostic-quality scans after just one hour of hands-on training.In May 2026, RIVANNA reported on the U.S. Food and Drug Administration’s 510(k) clearance of the Accuro® XV Diagnostic Ultrasound System for musculoskeletal imaging, authorizing commercial use across hospital and clinic settings.The company’s clinical program now spans eight sites nationwide with more than 1,500 patients enrolled.

The 2026 MedTech World Awards | North America, powered by Blue Goat Cyber, will be presented Monday, May 11, 2026, at the inaugural North American Awards Gala at the Hilton West Palm Beach, marking the first time the MedTech World Awards have been hosted in the United States.

About the MedTech Scale-Up of the Year Award
Presented by MedTech World, the MedTech Scale-Up of the Year category recognizes growth-stage medical technology companies demonstrating strong commercial momentum, expanding partnerships, and accelerating real-world adoption. The award is one of 22 categories spanning innovation, clinical excellence, regulatory strategy, investment, and leadership across the global MedTech ecosystem.

About RIVANNA
RIVANNA® is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company’s platform automates complex anatomical analysis at the point of care, enabling faster, more confident clinical decisions while reducing variability and expanding access to advanced capabilities. The first applications target significant market opportunities in regional anesthesia and fracture care. RIVANNA has built a proven FDA regulatory track record across its Accuro® platform, with device clearances for Accuro® 3S (spinal needle guidance) and Accuro® XV (musculoskeletal imaging), a portfolio of supporting cleared consumables, and AI software modules advancing through regulatory review. The company is backed by 100+ patents and validated through clinical partnerships with leading academic medical centers. RIVANNA is headquartered in Charlottesville, Virginia, and operates an FDA-registered, ISO 13485:2016-certified manufacturing facility. Learn more at rivannamedical.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rivanna-nominated-for-medtech-scale-up-of-the-year-at-medtech-world-awards-2026–north-america-302763342.html

SOURCE RIVANNA

Continue Reading

Technology

D2L Launch Week Highlights Latest Product Releases

Published

on

By

Latest innovations are designed to save time, simplify workflows, and help drive better learning outcomes

TORONTO, May 5, 2026 /PRNewswire/ – D2L, a global leader in learning innovation, hosted its first-ever D2L Launch Week, a four-day virtual webinar series spotlighting the company’s latest product innovations across D2L Brightspace in 2026.

Throughout the week, D2L showcased a range of product releases through live demos and practical customer use cases, highlighting how institutions, school districts and organizations can help to drive engagement and improve learning outcomes. The featured updates include enhancements to D2L Lumi for idea generation, intervention suggestions, quiz creation and summarization; tools to strengthen parent and guardian outreach; and administrative capabilities designed to help large organizations delegate course and configuration management more effectively.

“We’re proud to showcase the ways D2L continues to innovate to help make learning more personalized, efficient, and scalable,” said Christian Pantel, Chief Product Officer at D2L. “From new D2L Lumi features to enhanced communication tools and more flexible distributed administration capabilities, these updates are designed to help our customers save time, improve usability, and deliver better learning experiences at scale.”

Enhancements to D2L Lumi

Among the new capabilities were several updates to D2L’s AI-native tool, D2L Lumi, designed to improve usability, transparency, and alignment across workflows, including:

D2L Lumi Ideas: Generates assignment and discussion ideas directly within Brightspace, making it easier to generate high quality content aligned to learning outcomes.D2L Lumi Insights: Gives educators access to learning intervention suggestions, designed to provide recommended next steps based on learner data.D2L Lumi Quiz: Helps educators generate questions from multiple course content topics and includes a more streamlined question-generation workflow.D2L Lumi Summary: Supports summarization from more content sources, including nested submodules, and can give educators the ability to preview and adjust source text before summarization.

Updates to Parent and Guardian Communications

D2L also introduced new parent and guardian communication enhancements to help K-12 educators strengthen engagement beyond the classroom. Teachers can now send bulk emails to all parents and guardians associated with students in their class. For individual student outreach, teachers can also email parents and guardians of a specific learner, making it easier to share timely updates on student progress and classroom activity.

Manage Distributed Administration at Scale

Distributed Administration gives organizations more flexibility to delegate administrative responsibilities across organization levels. With Distributed Administration, administrators can manage specific areas, enabling them to oversee courses while helping to reduce bottlenecks and free up time.

Learn more about the latest product releases showcased at D2L Launch Week.

About D2L   
D2L is transforming the way the world learns, helping learners achieve more than they dreamed possible. Working closely with customers all over the world, D2L is on a mission to make learning more inspiring, engaging and human. Find out how D2L helps transform lives and delivers outstanding learning outcomes in K-12, higher education and businesses.

D2L Media Contact
PR@D2L.com
X: @D2L
© 2026 D2L Corporation.

The D2L family of companies includes D2L Inc., D2L Corporation, D2L Ltd, D2L Australia Pty Ltd, D2L Europe Ltd, D2L Asia Pte Ltd, D2L India Pvt Ltd, D2L Brasil Soluções de Tecnologia para Educação Ltda and D2L Sistemas de Aprendizaje Innovadores, S. D2 R.L de C.V., and H5P Group AS.

All D2L and H5P marks are owned by the D2L group of companies. Please visit D2L.com/trademarks for a list of D2L marks. All other trademarks are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/d2l-launch-week-highlights-latest-product-releases-302763345.html

SOURCE D2L

Continue Reading

Trending